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Effects of endothelin-1 on renal function in humans: Implications for
physiology and pathophysiology. Elevated levels of the vasocontrictor
peptide endothelin-1 have been demonstrated in various pathological
conditions that are characterized by sodium retention and/or renal
vasoconstriction, such as heart failure, hepatorenal syndrome, renal
failure and during administration of cyclosporin and radiocontrast. In the
present study we studied in seven healthy subjects the renal and endocrine
effects of systemic administration of endothelin-1 (0.5, 1.0 and 2.5
ng/kg/min). During endothelin-1 infusion plasma levels rose from 3.2
0.5 to respectively 5.0 0.8, 6.2 0.5 and 8.5 1.1 pmol/liter, values that
can also be observed in physiological and pathological conditions. Infusion
of low dosages of endothelin-1, that result in a twofold increase in plasma
levels, decreased sodium excretion by 36%, without a significant effect on
systemic and renal hemodynamics. Infusion of 2.5 ng/kglmin of endothe-
lin-1 further enhanced sodium retention and, in addition, increased renal
vascular resistance by 37%. Blood pressure did not change significantly.
Pretreatment with the calcium channel blocker nifedipine caused renal
vasodilation, which compensated for the renal vasocontriction by endo-
thelin-1 and prevented sodium retention. Apparently, endothelin-1 par-
ticipates in volume homeostasis in humans, whereas pathophysiologiocal
concentrations can contribute to renal vasoconstriction and sodium reten-
tion. Calcium channel blockers may protect against these effects of
endothelin-1.
Elevated levels of the vasoconstrictor peptide endothelin-1
have been demonstrated in many pathological conditions [1, 2].
Local factors such as thrombin, fluid-mechanical shear stress and
tumor necrosis factor can enhance endothelin synthesis by the
vascular endothelium [1]. These factors may contribute to the
elevated levels of endothelin found in conditions with generalized
endothelial damage such as atherosclerosis [3j and during cyclo-
sporin administration [4]. Elevated plasma levels of endothelin
have also been found in situations where effective circulating
volume is decreased, such as heart failure [5] and hepatorenal
syndrome [6], and in renal failure [7, 8].
It is possible that increased plasma levels of endothelin-1
contribute to the renal vasoconstriction, decreased GFR, and
sodium retention that occur in these pathological conditions.
However, the effects of systemic infusion of endothelin-1 in
humans have hardly been studied [9, 10], and have thus far
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focused on the effects on blood pressure and regional clearance of
endothelin. In the present study, we therefore investigated the
effects of increasing endothelin-1 dosages on renal hemodynamics
and excretory function and on endocrine function in men up to
plasma levels of 10 pmol!liter, levels found during the patho-
logical conditions mentioned above. At present no information is
available whether the renal effects of endothelin-1 can be pre-
vented in humans. Because recruitment of voltage-dependend
Ca2-channels probably contributes to the vasoconstrictive effect
of endothelin [11, we also investigated whether blockade of these
channels with the dihydropyridine nifedipine can modulate the
renal effects of endothelin-1 in humans, and in this way could be
used as a treatment modality.
Methods
Studies were carried out in seven healthy volunteers (co-
workers from the department of nephrology). Six were males, one
was female; their ages ranged from 27 to 33 years. The protocol
was approved by the University Hospital Ethical Committee for
study in humans (no. 93.93).
All subjects underwent two clearance studies (see below). One
study served as a time control study. During the other study
endothelin was infused at incremental dosages (respectively 0.5,
1.0 and 2.5 ng/kg/min). Four subjects underwent an additional
clearance study, during which the same quantities of endothelin
were infused in the presence of nifedipine. For this purpose
nifedipine infusion(priming dose 0.01 mg/kg, maintenance infu-
sion 0.01 mg/kg/hr; Bayer By, Mijdrecht, The Netherlands) was
started at 9 a.m. on the morning of the clearance study, and
continued throughout the study.
The subjects received a diet containing 200 mmol sodium and
100 mmol potassium per day. Adherence to the diet was con-
trolled by 24-hour urine collections. Lithium carbonate (400 mg)
was taken at 10 p.m. on the fourth day, and the subjects refrained
from food thereafter. On the morning of the fifth day the subjects
underwent a clearance study. At 9 a.m. a priming dose of a
solution containing 10% inulin, to measure glomerular filtration
rate (GFR), and 2.5% para-aminohippuric acid (PAH), to mea-
sure estimated renal plasma flow (ERPF), was administered,
followed by continuous infusion of this solution throughout the
remainder of the study. Maximal water diuresis was induced by an
oral water load of 25 ml/kg body weight, and was maintained by
drinking amounts of water matching urinary output. After at least
one hour equilibration, and only when urine osmolality was 70
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mOsmlkg or less, two 20-minute urine baseline collections were
obtained by spontaneous voiding. Blood specimens were drawn at
the midpoint of each collection period from the contralateral
forearm. Thereafter endothelin-1 infusion was started via a sep-
arate antecubital vein, Endothelin-1 (Peptide Institute mc, Scien-
tific Marketing Associates, Herst, UK) was dissolved in haemaccel
and administered for 40 minutes in a dosage of 0.5 ng/kg/min,
followed by a 40 minute infusion in a dosage of 1.0 nglkg/min and
a further 40 minute infusion with 2.5 nglkg/min. The infusion
period was followed by a recovery period of 120 minutes. Urine
and blood sampling was continued at 20 minute intervals through-
out the whole study. Samples for determination of plasma endo-
thelin were obtained before endothelin-1 infusion, and every 40
minutes during the endothelin-1 infusion and recovery. Plasma
renin (PRA), aldosterone and ANP were measured in blood
samples drawn before, following 120 minutes of endothelin infu-
sion and after 120 minutes of recovery.
Blood pressure and heart rate were recorded at five minute
intervals during the clearance studies using an automatic oscil-
lometer device (Omega 2000, Invivo Research Laboratory Inc.
Tulsa, Oklahoma, USA). Mean arterial blood pressure was cal-
culated as the sum of one-third of the systolic pressure and
two-thirds of the diastolic pressure. Blood and urine samples were
analysed for sodium and potassium by flame photometry, lithium
(Perkin-Elmer 3030 Atomic Absorption Spectrophotometer) and
osmolality by freezing point depression. Inulin was hydrolyzed to
fructose and measured by photometry with indolacetic acid [12],
and PAH was determined photometrically by a chromaldehyde
reaction [13]. PRA, aldosterone and ANP were determined by
radioimmunoassay, as described previously [14]. Blood samples
for determination of endothelin-1 were collected in prechilled
potassium EDTA containing tubes and centrifuged at 4°C. The
plasma samples were stored at —70°C until the assay. Endothelin
was extracted from plasma by solid phase extraction with 6-ml
octadecyl columns (Baker, Phillipsburg, New Jersey, USA). After
conditioning of the columns with methanol and deionized water,
2 ml of plasma acidified with 4 ml 0.5% trifluoroacetic acid (TFA)
was applied to the columns and extracted, followed by washing
with 6 ml 0.5% TFA and 6 ml deionized water, and elution with
2 ml 0.1% TFA in methanol: water 9:1 vol/vol. The eluate was
dried under nitrogen at 40°C, the residue was dissolved in 250 1.d
assay buffer, and 100 jd aliquots were analyzed in duplicate. The
recovery of endothelin throughout the procedure was 75%.
Endothelin-1 was determined with radioimmunoassay kits (Pen-
insula Laboratories Europe, Merseyside, UK). Cross-reactivities
of endothelin-2 and endothelin-3 are 7%, and of pro-endothelin-1
17%. The reported concentrations (pmol/liter) are corrected for
procedural losses. Sensitivity of the assay was 0.3 fmol per assay
tube; within-assay and between-assay coefficients of variation were
9% and 13% at a level of 3.6 pmol/liter, respectively.
Calculations and statistics
Reported values represent means standard error. PRA and
aldosterone were analyzed after logarithmic transformation. Re-
nal blood flow was calculated by dividing ERPF by (1-packed cell
volume), and renal vascular resistance was calculated by dividing
arterial pressure by renal blood flow. Statistical analysis was
performed using two-way analysis of variance of a randomized
block design to compare the endothelin infusion to time control.
Plasma endothelin levels were analyzed with one-way analysis of
variance, as plasma levels were less frequently sampled during the
time-control study. If variance ratios reached statistical signifi-
cance, the differences between the means were analyzed with the
Studentized Newman-Keuls test for P < 0.05 and P < 0.01.
Results
Twenty-four-hour urine sodium excretions were 210 22, 190
31 and 194 44 mmol on the days before the time-control
study, endothelin infusion study and endothelin with nifedipine
infusion study, respectively. Endothelin-1 infusion was well toler-
ated in the dosages used, and no side effects were observed.
Effects of endothelin-1 on electrolyte excretion
Sodium excretion decreased progressively during endothelin-1
infusion from a baseline value of 196 33 .tmol/min to 79 13
mol/min during the highest dosage of endothelin. After cessa-
tion of the endothelin-1 infusion sodium excretion did not return
to levels observed during the time control study (Fig. 1). Frac-
tional sodium excretion (that is, corrected for differences in
filtered load) decreased parallel to sodium excretion from a
baseline value of 1.24 0.2 to 0.56 0.1% during 2.5 nglkg/min
endothelin-i infusion (P < 0.01, compared to time control). The
decrease in sodium excretion was accompanied by a progressive
decrease in fractional excretion of lithium (24.0 2.3 to 18.9
1.7%, P < 0.01) and maximal urine flow (14 ito 8 1 ml/min,
P < 0.01), whereas urine osmolality did not change (66 4 to 64
4 mOsm/kg). Potassium excretion during endothelin-i infusion
did not differ from time-control observations.
Effects of endothelin-1 on hemodynamics
Endothelin-1 did not result in a significant increase in blood
pressure, although a tendency towards a higher blood pressure
was noted during the highest dose of endothelin (91 2 to 94
2 mm Hg, not significant). Heart rate did not change (57 2 to 55
2 beats/mm). GFR did not change significantly until the highest
dose of endothelin, during which it decreased from 121 8 to 109
9 ml/min (P < 0.05). Similarly, ERPF did not change signifi-
cantly except during the highest endothelin infusion (Fig. 2). The
decrease in renal plasma flow at this dosage proportionally
exceeded the decrease in GFR, as reflected by an increase in
filtration fraction from 20.6 1.5 to 24.5 2.0% (P < 0.01). As
a result of these hemodynamic changes, calculated renal vascular
resistance increased during the 2.5 ng/kg/min endothelin infusion
from 82 3 to 112 5mm Hg mm/liter (P < 0.01), but was not
significantly different from time-control measurements during the
other dosages of endothelin-1.
Effects of endothelin-1 on hormones
Infusion of endothelin-1 resulted in a threefold increase of
plasma endothelin (Fig. 3). Plasma renin activity, plasma aldoste-
rone and ANP levels did not change significantly during endothe-
lin infusion (from 164 59 to 131 62 fmol liter/second, 242
57 to 217 61 pmol/liter and from 10 2 to 12 4 pmol/liter,
respectively).
Endothelin-1 infusion in the presence of nifedipine
Baseline sodium excretion in the subjects who participated in
both the endothelin-1 infusion studies was 214 62 prnol/min
during the control endothelin infusion and 238 53 smol/min
during the nifedipine study. Baseline blood pressure was similar
—200
Fig. 1. Changes in sodium excretion ( UV, lower panel), renal plasma
flow (ERPF, middlepanel) and mean arterial blood pressure (upper panel)
during endothelin infusion (0) versus time-control (•) in 7 subjects. Values
are means SEM. Each values represents the mean of 20 minutes.
Endothelin-1 (ET-1) was given at incremental dosages of 0.5, 1.0 and 2.5
nglkglmin for 40 minute periods (indicated by the boxes), followed by
2-hour recovery measurements.
—150
—200
Fig. 2. Changes in sodium excretion ( UNV lower panel), renal plasma
flow (ERPF, middle panel) and mean arterial blood pressure (upper panel)
during endothelin infusion (0) and endothelin infusion after nifrdipine
pretreatment (•) in 4 subjects. Values are means SEM. Each values
represents the mean of 20 minutes. Endothelin-1 (ET-1) was given at
similar dosages as in Figure 1.
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between the control endothelin infusion and the nifedipine study
(89 2 and 88 2 mm Hg, respectively). In the nifedipine study
there was a trend towards a lower sodium excretion during
endothelin infusion when compared to pre-infusion values, which
was caused by a slight antinatriuresis in two subjects. However,
sodium excretion exceeded that during time control in all subjects
during the whole infusion period. Cessation of the endothelin
infusion was followed by an increase in sodium excretion in all
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ficient to compensate for the endothelin-1-induced renal vaso-
constriction.
At the lower dosages of endothelin-1 sodium excretion
decreased in the absence of significant changes in filtration,
whereas after discontinuation of endothelin-1 renal hemody-
namics rapidly normalized, while sodium retention continued
(Fig. 1). This indicates that endothelin-1 may directly stimulate
tubular sodium reabsorption. The decrease in sodium excretion
was accompanied by a fall in fractional excretion of lithium and
maximal urine flow. With appropriate reserve, this could
indicate an increase in proximal tubule sodium reabsorption
and/or increased sodium reabsorption in the thin segments of
Henle's loop [16]. The precise mechanism of this sodium
retention is unclear at the moment. In animals studies no
receptors for ET could be identified in the proximal nephron
[17]. This may indicate that the endothelin-receptor distribu-
tion may differ among species. Alternatively, the stimulatory
effects on sodium reabsorption in the proximal nephron are
secondary to renal hemodynamic changes, such as a redistri-
bution of renal blood flow towards the cortex, which increases
sodium reabsorption in medullary nephron populations but
does not alter whole kidney blood flow. The marked antinatri-
uretic effect of endothelin-1 in humans is in contrast with
animal studies. Most of these studies demonstrated a natri-
uretic effect of low dose systemic administration of endothe-
lin-1 despite a fall in GFR and renal blood flow [18—20]. This
natriuresis may be due to stimulation of ANP [21, 22] or
pressure-natriuresis secondary to a higher blood pressure
during endothelin infusion. Studies in the isolated perfused
kidney have also shown an increase in sodium excretion after
endothelin-1 administration [23]. Systemic infusions with high
doses of endothelin-1 in dogs decreased sodium excretion
because of reduction in filtered load and/or renin-angiotensin
stimulation [24, 25]. It should be noticed, however, that in the
present study sodium excretion decreased during the lower
dosages of endothelin-1 in the absence of a change in filtered
load or in activity of the renin-angiotensin system.
In contrast to the antinatriuretic effect of endothelin-1
infusion, which already appeared during the lower dosages of
endothelin, renal vasoconstriction in our study occurred only at
the highest dosage of endothelin. At this dose renal vascular
resistance increased by approximately 37%. Similarly, GFR
decreased only at the highest dose of endothelin-1. Impor-
tantly, blood pressure did not change at this endothelin-1
dosage. This suggests that elevations of endothelin-1 in hu-
mans, unlike other vasopressor systems such as angiotensin II,
do not contribute to acute blood pressure regulation. Of
course, it is very well possible that the renal effects of endo-
thelin-1 contribute to long-term blood pressure regulation.
At least two intracellular signaling pathways for the hemo-
dynamic effects of endothelin have been identified thus far.
Endothelin increases membrane diacyiglycerol, thus activating
protein kinase C, and endothelin induces phosphatidylinositol
breakdown, which results in release of Ca2 from intracellular
stores [26, 27]. The increase in inositol triphosphate and/or
calcium activates voltage-dependent calcium channels, thereby
also mobilizing extracellular calcium. The latter pathway sug-
gests that blockade of these voltage-dependent Ca2 channels
may also modulate the effects of endothelin. However, the
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Fig. 3. Plasma endothelin-1 levels during endothelin infusion (0), time-
control (•) in 7 subjects and during endothelin infusion after nifedipine
treatment (V) in 4 subjects. Values are means SEM. Each value
represents the mean of 40 minutes. # P < 0.05, ## P < 0.01 compared
to baseline for the endothelin study. Endothelin-1 (ET-1) was given at
similar dosages as in Figure 1.
subjects. Baseline ERPF was increased and renal vascular resis-
tance decreased during nifedipine pretreatment in all subjects,
when compared to the baseline value in the endothelin infusion
study (717 7 mI/mm vs. 595 33 ml/min and 69 2 vs. 81
2 mm Hg mm/liter, respectively). Renal plasma flow fell during
endothelin infusion in the nifedipine study (Fig. 2) and renal
vascular resistance increased from 69 2 to 79 3 mm
Hg mm/liter. However, ERPF exceeded baseline levels of the
endothelin study during all clearance periods, while renal vascular
resistance did not increase above time-control levels. GFR did not
change during endothelin-1 infusion in the nifedipine study, and
filtration fraction increased from 18.4 1.0 to 20.0 0.5% in all
subjects. Increments in plasma endothelin were comparable be-
tween the two studies (Fig. 3).
Discussion
The present study shows that infusion of endothelin-1 in low
dosages in humans causes renal sodium retention, whereas a
higher dosage of endothelin causes strong sodium retention
and, in addition, renal vasoconstriction. The lowest antinatri-
uretic dosages doubled plasma endothelin-1 concentrations.
The highest dosage increased plasma endothelin-1 threefold, to
concentrations seen in pathophysiological conditions, such as
heart failure, hepatorenal syndrome and renal failure [5—8].
Therefore, our study is the first to show functional information
that physiological concentrations of endothelin-1, such as that
observed during upright tilt [15], participate in volume ho-
meostasis, whereas pathophysiological concentrations can con-
tribute to renal vasoconstriction and sodium retention. Finally,
our data also demonstrate that nifedipine prevents the antina-
triuresis by endothelin-1, and causes renal vasorelaxation suf-
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observed effects of Ca2 antagonists on vasoconstriction in-
duced by endothelin-1 vary greatly, and seem to depend on the
blood vessels and species studied, as well as the experimental
conditions, such as endothelin dosage [2]. The Ca2 antagonist
manidipine was capable of near-total reversal of the effects of
endothelin on blood pressure and renal blood flow in rats [28],
while other studies in intact animals failed to show effects of
Ca2 antagonists on the renal vasoconstrictive properties of
endothelin [29, 30], or could only demonstrate an attenuation
at lower dosages of endothelin [31, 32]. The present study
shows that pretreatment with nifedipine at a dosage that does
not affect blood pressure can compensate for both the renal
vasoconstrictive and antinatriuretic effects of endothelin. Some
effect of endothelin still can be observed, which is not surpris-
ing in view of the existence of other intracellular signaling
pathways. Alternatively, one has to consider the possibility that
the attenuation of the effects of endothelin during nifedipine
infusion was aspecific by resetting renal blood flow and sodium
excretion to levels higher than baseline. Nevertheless, irrespec-
tive of the mechanism, renal perfusion and sodium excretion
never fell below control levels. This observation suggests a
renal protective effect of Ca2 antagonists in pathological
conditions, which are associated with elevation of plasma
endothelin such as contrast administration [33], post-ischemic
renal failure [7] and administration of cyclosporin [4]. It also
coincides with some recent observations that Ca2 antagonists
decrease renal vasoconstriction and improve renal transplant
survival in renal transplant recipients treated with cycloporin
[34, 35].
The present study demonstrates a role for endothelin in
physiological volume homeostasis, as well as in pathological
volume derangements and during loss of renal function in men
by inducing renal vasoconstriction and sodium retention. Cal-
cium channel blockers may prevent these effects of endothelin.
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